MDM-2/p53

The p53 tumor suppressor is a principal mediator of growth arrest, senescence, and apoptosis in response to a broad array of cellular damage. p53 is a short-lived protein that is maintained at low, often undetectable, levels in normal cells. Under stress conditions, the p53 protein accumulates in the cell, binds in its tetrameric form to p53-response elements and induces the transcription of various genes.

MDM-2 is transcriptionally activated by p53 and MDM-2, in turn, inhibits p53 activity in several ways. MDM-2 binds to the p53 transactivation domain and thereby inhibits p53-mediated transactivation. MDM-2 also contains a signal sequence that is similar to the nuclear export signal of various viral proteins and, after binding to p53, it induces its nuclear export. As p53 is a transcription factor, it needs to be in the nucleus to be able to access the DNA; its transport to the cytoplasm by MDM-2 prevents this. Finally, MDM-2 is a ubiquitin ligase, so is able to target p53 for degradation by the proteasome.

In many tumors p53 is inactivated by the overexpression of the negative regulators MDM2 and MDM4 or by the loss of activity of the MDM2 inhibitor ARF. The pathway can be reactivated in these tumors by small molecules that inhibit the interaction of MDM2 and/or MDM4 with p53. Such molecules are now in clinical trials.
| **MDM-2/p53 Inhibitors, Activators, MDM2 Inhibitors, p53 Activators & p53 Inhibitors** |
|---------------------------------|---------------------------------|
| **Alrizomadlin**<br>(APG-115; AA-115)  | **AM-8735**<br>Cat. No.: HY-101518 |
| Alrizomadlin (APG-115) is an orally active MDM2 protein inhibitor binding to MDM2 protein with IC₅₀ and Kₖ values of 3.8 nM and 1 nM, respectively. Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner.<br>Purity: 98.16%<br>Clinical Data: Phase 2<br>Size: 1 mg, 5 mg, 10 mg | AM-8735 is a potent and selective MDM2 inhibitor with an IC₅₀ of 25 nM.<br>Purity: >98%<br>Clinical Data: No Development Reported<br>Size: 1 mg, 5 mg |
| **Amifostine**<br>(WR2721)  | **Amifostine thiol**<br>(WR-1065)  | **Amifostine thiol dihydrochloride**<br>(WR-1065 dihydrochloride)  | **Amifostine trihydrate**<br>(WR2721 trihydrate)  | **BI-0252**<br>Cat. No.: HY-100765 |
| Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer.<br>Purity: ≥98.0%<br>Clinical Data: Launched<br>Size: 10 mM × 1 mL, 10 mg, 50 mg | Amifostine thiol (WR-1065) is an active metabolite of the cytoprotector Amifostine (HY-B0639). Amifostine thiol is a cytoprotective agent with radioprotective abilities. Amifostine thiol activates p53 through a JNK-dependent signaling pathway.<br>Purity: ≥90.0%<br>Clinical Data: No Development Reported<br>Size: 10 mg | Amifostine thiol dihydrochloride can protect normal tissues from the toxic effects of certain cancer drugs and activate p53 through a JNK-dependent signaling pathway.<br>Purity: ≥98.0%<br>Clinical Data: No Development Reported<br>Size: 10 mM × 1 mL, 5 mg, 10 mg | Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy.<br>Purity: >98%<br>Clinical Data: Launched<br>Size: 1 mg, 5 mg | BI-0252 is an orally active, selective MDM2-p53 inhibitor with an IC₅₀ of 4 nM. BI-0252 can induce tumor regressions in all animals of a mouse SJSA-1 xenograft, with concomitant induction of the tumor protein p53 (TP53) target genes and markers of apoptosis.<br>Purity: >98%<br>Clinical Data: No Development Reported<br>Size: 1 mg, 5 mg |
| **BH3I-1**<br>(BH1; BH 3I)  | **CPL0137 hydrochloride**<br>(Curaxin-137 hydrochloride; CBL-137 hydrochloride)  | **COTI-2**<br>Cat. No.: HY-19896 |
| BH3I-1 is a Bcl-2 family antagonist, which inhibits the binding of the Bak BH3 peptide to Bcl-XL with a Kᵢ of 2.4±0.2 μM in FP assay. BH3I-1 has a Kᵢ of 5.3 μM against the p53/MDM2 pair.<br>Purity: ≥98.0%<br>Clinical Data: No Development Reported<br>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | CPL0137 hydrochloride is an inhibitor of the histone chaperone, FACT. CPL0137 hydrochloride can also activate p53 and inhibits NF-κB with IC₅₀ of 0.37 and 0.47 μM, respectively.<br>Purity: 99.21%<br>Clinical Data: Phase 1<br>Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg | COTI-2, an anti-cancer drug with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines.<br>Purity: 98.96%<br>Clinical Data: No Development Reported<br>Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
CP-31398 dihydrochloride

Cat. No.: HY-18343A

CP-31398 dihydrochloride stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53.

Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DPBQ

Cat. No.: HY-U00441

DPBQ activates p53 and triggers apoptosis in a polyplody-specific manner, but does not inhibit topoisomerases or bind DNA. DPBQ elicits expression and phosphorylation of p53 and this effect is specific to tetraploid cells.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

HLI373

Cat. No.: HY-108640

HLI373 is an efficacious Hdm2 inhibitor. HLI373 inhibits the ubiquitin ligase activity of Hdm2. HLI373 is effective in inducing apoptosis of several tumor cells that are sensitive to DNA-damaging agents. Antimalarial activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Idasanulin (RG7388)

Cat. No.: HY-15676

Idasanulin (RG7388) is a potent and selective MDM2 antagonist, inhibiting p53-MDM2 binding, with an IC_{50} of 6 nM.

Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ivaltinostat (CG-200745)

Cat. No.: HY-16138

Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin.

Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ivaltinostat formic (CG-200745 formic)

Cat. No.: HY-16138A

Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin.

Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

CTX1

Cat. No.: HY-U00442

CTX1 is a p53 activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Eprenetapopt (APR-246; PRIMA-1Met)

Cat. No.: HY-19980

Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells.

Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Inauhzin (INZ)

Cat. No.: HY-15869

Inauhzin is a dual SirT1/IMPDH2 inhibitor, and acts as an activator of p53, used in the research of cancer.

Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HLI373 dihydrochloride

Cat. No.: HY-108640A

HLI373 dihydrochloride is an efficacious Hdm2 inhibitor. HLI373 dihydrochloride inhibits the ubiquitin ligase activity of Hdm2. HLI373 dihydrochloride is effective in inducing apoptosis of several tumor cells that are sensitive to DNA-damaging agents. Antimalarial activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg
**Kevetrin hydrochloride** (4-isothioureidobutyronitrile hydrochloride; ...)  
Cat. No.: HY-16271

Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.

- **Purity:** ≥98.0%
- **Clinical Data:** Phase 2
- **Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

**MB710**  
Cat. No.: HY-120373

MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a $K_d$ of 41.1 μM. MB710 shows anticancer activity in p53-Y220C cell lines.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 5 mg, 10 mg, 25 mg, 50 mg

**MD-222**  
Cat. No.: HY-134823

MD-222 is the first-in-class highly potent PROTAC degrader of MDM2. MD-222 consists of ligands for Cereblon and MDM2. MD-224 induces rapid degradation of the MDM2 protein and activation of wild-type p53 in cells. MD-222 has anticancer effects.

- **Purity:** 99.28%
- **Clinical Data:** No Development Reported
- **Size:** 5 mg, 10 mg, 25 mg

**MDM2-IN-1**  
Cat. No.: HY-130684

MDM2-IN-1 (Compound 30) is a synthetic MDM2-p53 interaction (MDM2) inhibitor and contains the trans (D-)configuration.

- **Purity:** 95.13%
- **Clinical Data:** No Development Reported
- **Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**MI-1061**  
Cat. No.: HY-125858

MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor ($IC_{50}$=4.4 nM, $K_i=0.16$ nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.

- **Purity:** 99.62%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

**MA242**  
Cat. No.: HY-112816

MA242 is a dual inhibitor of murine double minute 2 (MDM2) and nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

**MC-VC-PABC-SP 141**  
Cat. No.: HY-136320

MC-VC-PABC-SP 141 is a drug-linker conjugate for ADC with potent antitumor activity by using SP 141 (a potent MDM2 inhibitor), linked via the cleavable ADC linker MC-VC-PABC.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**MD-224**  
Cat. No.: HY-114312

MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (MDM2) degrader based on the proteolysis-targeting chimera (PROTAC) concept. MD-224 consists of ligands for Cereblon and MDM2.

- **Purity:** 99.74%
- **Clinical Data:** No Development Reported
- **Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**MDM2-IN-21**  
Cat. No.: HY-139458

MDM2-IN-21 is a potent MDM2 inhibitor. MDM2-IN-21 can be used for the research of cancer.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

**MI-1061 TFA**  
Cat. No.: HY-125858A

MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor ($IC_{50}$=4.4 nM, $K_i=0.16$ nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg, 10 mg
MI-773

MI-773 is a potent MDM2-p53 protein-protein interaction (PPI) inhibitor with high binding affinity against MDM2 (Kd=8.2 nM). MI-773 has antitumor activity.

| Purity: | 98.05% |
| Clinical Data: | No Development Reported |
| Size: | 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

Milademetan (DS-3032)

Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis.

| Purity: | 98.33% |
| Clinical Data: | Phase 2 |
| Size: | 10 mM x 1 mL, 1 mg, 5 mg, 10 mg |

Milademetan tosylate hydrate (DS-3032b, DS-3032 tosylate hydrate)

Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis.

| Purity: | 98.21% |
| Clinical Data: | Phase 2 |
| Size: | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

MS7972

MS7972 is a small molecule that blocks human p53 and CREB binding protein association. MS7972 can almost completely block this BRD interaction at 50 μM.

| Purity: | 99.81% |
| Clinical Data: | No Development Reported |
| Size: | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

Navtemadlin (AMG 232; KRT-232)

Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC50 of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM.

| Purity: | 99.43% |
| Clinical Data: | Phase 1 |
| Size: | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

NSC 146109 hydrochloride

NSC 146109 hydrochloride is a small-molecule p53 activator that target MDMX and can be used for breast cancer research. NSC 146109 hydrochloride is a pseudouracil derivative, promotes breast cancer cells to undergo apoptosis through activating p53 and inducing expression of proapoptotic genes.

| Purity: | 99.60% |
| Clinical Data: | No Development Reported |
| Size: | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

NSC 66811

NSC 66811 is a MDM2-p53 inhibitor, with a Kd of 120 nM for binding to MDM2.

| Purity: | 98.12% |
| Clinical Data: | No Development Reported |
| Size: | 10 mM x 1 mL, 5 mg |

NSC-207895 (XI-006)

NSC-207895 (XI-006), a DNA damaging agent, is an anticancer agent and p53 activator.

<p>| Purity: | &gt;98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |</p>
<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>Name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HY-159726</td>
<td>NSC319726 (ZMC1)</td>
<td>A mutant p53R175 reactivator; inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM); shows no inhibition for p53 wild-type cells.</td>
</tr>
<tr>
<td>HY-10029</td>
<td>NVP-CGM097 (CGM097)</td>
<td>A potent and selective MDM2 inhibitor with IC50 of 1.7±0.1 nM for hMDM2.</td>
</tr>
<tr>
<td>HY-31435</td>
<td>NVP-CGM097 sulfate (CGM097 sulfate)</td>
<td>A potent and selective MDM2 inhibitor with IC50 of 1.7±0.1 nM for hMDM2.</td>
</tr>
<tr>
<td>HY-159726</td>
<td>NVP-CGM097 (CGM097)</td>
<td>A potent and selective MDM2 inhibitor with IC50 of 1.7±0.1 nM for hMDM2.</td>
</tr>
<tr>
<td>HY-10029</td>
<td>NVP-CGM097 (Rebemadlin)</td>
<td>A potent Murine Double Minute 2 (MDM2) inhibitor (IC50=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis.</td>
</tr>
<tr>
<td>HY-15335</td>
<td>Nutlin-3b</td>
<td>A p53/MDM2 inhibitor with an IC50 of 13.6 μM. Nutlin-3b is 150 times less potent in binding to MDM2 than Nutlin-3a.</td>
</tr>
<tr>
<td>HY-50696</td>
<td>Nutlin-3a (Rebemadlin)</td>
<td>A potent and selective MDM2 inhibitor with IC50 of 1.7±0.1 nM for hMDM2.</td>
</tr>
<tr>
<td>HY-18734</td>
<td>No Development Reported</td>
<td>No development reported.</td>
</tr>
<tr>
<td>HY-P1755</td>
<td>p53 (17-26)</td>
<td>p53 (17-26) is amino acids 17 to 26 fragment of p53. p53 (17-26) is mdm-2-binding domain.</td>
</tr>
</tbody>
</table>

**General Information:**
- **Purity:**
  - NSC319726 (ZMC1): 98.07%
  - Nutlin-3: 99.18%
  - Nutlin-3a (Rebemadlin): 98.07%
  - NVP-CGM097 (CGM097): 98.52%
  - p53 (17-26): >98%
  - Nutlin-3b: >98.0%
  - p53 and MDM2 proteins-interaction-inhibitor (chiral): 97.77%
  - p53 and MDM2 proteins-interaction-inhibitor (racemic): >98%
- **Clinical Data:**
  - No Development Reported
- **Size:**
  - 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
  - 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

**Related Information:**
- **IC50:**
  - 1.7±0.1 nM for hMDM2.
  - 13.6 μM for p53/MDM2 interaction.
- **Autophagy:**
  - Stabilizes the p53 protein.
- **Apoptosis:**
  - Nutlin-3a (Rebemadlin) induces cell autophagy and apoptosis.
- **p53:**
  - p53 (17-26) is amino acids 17 to 26 fragment of p53.
  - p53 (17-26) is mdm-2-binding domain.
p53 and MDM2 proteins-interaction-inhibitor dihydrochloride

Cat. No.: HY-70027A

Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 100 mg

PhiKan 083

Cat. No.: HY-108637

PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a $K_d$ of 167 μM. PhiKan 083 can be used for cancer research.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Pifithrin-α hydrobromide
(Pifithrin hydrobromide; PFTα hydrobromide)

Cat. No.: HY-15484

Pifithrin-α hydrobromide is a p53 inhibitor which blocks its transcriptional activity and prevents cells from apoptosis. Pifithrin-α hydrobromide is also an aryl hydrocarbon receptor (AhR) agonist.

Purity: 95.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Pifithrin-β
(PFT β; Cyclic Pifithrin-α)

Cat. No.: HY-16702

Pifithrin-β (PFT β) is a potent p53 inhibitor with an $IC_{50}$ of 23 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pifithrin-μ
(PFTμ; 2-Phenylethynesulfonamide)

Cat. No.: HY-10940

Pifithrin-μ is an inhibitor of p53 and HSP70, with antitumor and neuroprotective activity.

Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

PK11000

Cat. No.: HY-U00447

PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 by covalent cysteine modification, without compromising DNA binding.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

P53R3

Cat. No.: HY-122578


Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PhiKan 083 hydrochloride

Cat. No.: HY-108637A

PhiKan 083 hydrochloride is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a $K_d$ of 167 μM, and a relative binding affinity ($K_d$) of 150 μM in Lnc229 cells.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg
PK11007
Cat. No.: HY-128784
PK11007 is a mild thiol alkylator with anticancer activity. PK11007 stabilizes p53 via selective alkylation of two surface-exposed cysteines without compromising its DNA binding activity. PK11007 induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels.
Purity: 99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PRIMA-1
Cat. No.: HY-19980A
PRIMA-1 (NSC-281668) is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

PROTAC MDM2 Degrader-1
Cat. No.: HY-128840
PROTAC MDM2 Degrader-1 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-1 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.
Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

PROTAC MDM2 Degrader-2
Cat. No.: HY-128841
PROTAC MDM2 Degrader-2 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-2 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.
Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

PROTAC MDM2 Degrader-3
Cat. No.: HY-128842
PROTAC MDM2 Degrader-3 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.
Purity: 98.69%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC MDM2 Degrader-4
Cat. No.: HY-128843
PROTAC MDM2 Degrader-4 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ReAcp53
Cat. No.: HY-P0121
ReAcp53 could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.
Purity: 99.39%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

RG7112
Cat. No.: HY-10959
RG7112 is a potent, selective, first clinical, orally active and blood-brain barrier crossed MDM2-p53 inhibitor, with an IC_{50} of 18 nM and a K_{d} of 11 nM for binding to MDM2.
Purity: 99.91%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RO-5963
Cat. No.: HY-120086
RO-5963 is a dual p53-MDM2 and p53-MDMX inhibitor with IC_{50} of ~17 nM and ~24 nM, respectively.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

www.MedChemExpress.com
### RO8994
**Cat. No.:** HY-16999  
RO8994 is a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitor, with IC50 of 5 nM (HTF binding assays) and 20 nM (MTT proliferation assays).

**Purity:** 99.30%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Sanggenol L
**Cat. No.:** HY-N2602  
Sanggenol L induces caspase-dependent and caspase-independent apoptosis in melanoma skin cancer cells. Sanggenol L induces of apoptosis via suppression of P38/Akt/mTOR signaling and cell cycle arrest via activation of p53 in p.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

### SAR405838
**Cat. No.:** HY-18986  
SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a Kᵣ of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity.

**Purity:** 93.06%  
**Clinical Data:** Phase 1  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### SCH529074
**Cat. No.:** HY-110088  
SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD (DNA binding domain) with a Kᵣ of 1-2 μM in a saturable manner.

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg

### Serdemetan
**Cat. No.:** HY-12025  
Serdemetan(JNI-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.

**Purity:** 99.23%  
**Clinical Data:** Phase 1  
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

### Siremadlin
**Cat. No.:** HY-18658  
Siremadlin(NVP-HDM201; HDM201) is a potent, orally bioavailable and highly specific p53-MDM2 interaction inhibitor.

**Purity:** 99.82%  
**Clinical Data:** Phase 2  
**Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

### SJ-172550
**Cat. No.:** HY-16664  
SJ-172550 is a small molecule inhibitor of MDMX, competes for the wild type p53 peptide binding to MDMX with an EC₅₀ of 5 μM.

**Purity:** ≥98.0%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 10 mg, 50 mg

### Solasodine
**Cat. No.:** HY-N0068  
Solasodine (Purapuridine; Solancarpidine; Solasodin) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities.

**Purity:** 98.86%  
**Clinical Data:** No Development Reported  
**Size:** 10 mg, 50 mg, 100 mg

### SP-141
**Cat. No.:** HY-110182  
SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells.

**Purity:** 99.30%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### Tenovin-1
**Cat. No.:** HY-13423  
Tenovin-1, a p53 activator, protects p53 from MDM2-mediated degradation. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also a dihydroorotate dehydrogenase (DHODH) inhibitor.

**Purity:** 99.88%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 50 mg, 100 mg
Tenovin-3

Cat. No.: HY-19339

Tenovin-3 is a p53 activator.

Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Tenovin-6

Cat. No.: HY-15510

Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC50s of 21 μM, 10 μM, and 67 μM, respectively.

Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tenovin-6 Hydrochloride

Cat. No.: HY-15510B

Tenovin-6 Hydrochloride, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Teprasiran

Cat. No.: HY-132595

Teprasiran (QPI-1002) is a small interfering RNA that temporarily inhibits p53-mediated cell death that underlies acute kidney injury (AKI).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Triglycidyl isocyanurate

Cat. No.: HY-W011434

Triglycidyl isocyanurate (TGIC, Teroxirone) is a triazine triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via p53 activation.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

UC2288

Cat. No.: HY-112780

UC2288 is a novel, cell-permeable, and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201).

Purity: 99.82%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Verminoside

Cat. No.: HY-N1094

Verminoside is an iridoid isolated from Kigelia africana, exhibits anti-inflammatory and remarkable antioxidant activity with a radical-scavenging activity of 2.5 μg/mL. The genotoxicity of Verminoside on human lymphocytes is associated with elevated levels of PARP-1 and p53 proteins.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YH239-EE

Cat. No.: HY-12287

YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent. IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction.

Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ziyuglycoside I

Cat. No.: HY-N0331

Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics.

Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

www.MedChemExpress.com